NRx Financial Statements From 2010 to 2024

NRXPW Stock  USD 0.05  0  2.00%   
NRx Pharmaceuticals financial statements provide useful quarterly and yearly information to potential NRx Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on NRx Pharmaceuticals financial statements helps investors assess NRx Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting NRx Pharmaceuticals' valuation are summarized below:
Market Capitalization
714.6 M
Earnings Share
(6.25)
There are over one hundred nineteen available fundamental ratios for NRx Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should should check NRx Pharmaceuticals' last-minute fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable.
Check NRx Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NRx Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.8 K, Interest Expense of 114 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NRx financial statements analysis is a perfect complement when working with NRx Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of NRx Pharmaceuticals Correlation against competitors.
For more information on how to buy NRx Stock please use our How to Invest in NRx Pharmaceuticals guide.

NRx Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets6.9 M7.3 M49 M
Slightly volatile
Other Current LiabilitiesM5.3 M7.3 M
Slightly volatile
Total Current Liabilities14.9 M19 M7.4 M
Slightly volatile
Accounts Payable2.3 M4.6 M1.2 M
Slightly volatile
Cash8.6 M4.6 M4.4 M
Slightly volatile
Non Current Assets Total409.4 K431 K43.7 M
Slightly volatile
Cash And Short Term Investments8.6 M4.6 M4.4 M
Slightly volatile
Common Stock Total Equity2.32.421.8 K
Slightly volatile
Common Stock Shares Outstanding7.2 M7.6 M12.4 M
Slightly volatile
Short Term Investments5.1 M5.4 M45.6 M
Slightly volatile
Liabilities And Stockholders Equity6.9 M7.3 M49 M
Slightly volatile
Other Current AssetsM2.3 M1.5 M
Slightly volatile
Other Stockholder Equity253.4 M241.3 M70 M
Slightly volatile
Total Liabilities15.7 M19 M7.8 M
Slightly volatile
Total Current Assets10.8 M6.9 M5.6 M
Slightly volatile
Common Stock79.8 K84 K40.3 M
Slightly volatile
Short and Long Term Debt Total9.6 M9.2 M2.6 M
Slightly volatile
Net Tangible Assets1.7 M1.9 M2.1 M
Slightly volatile
Long Term Debt1.9 M3.2 M1.1 M
Slightly volatile
Capital Surpluse2.3 M2.5 M2.8 M
Slightly volatile
Short and Long Term Debt4.8 M9.2 M1.7 M
Slightly volatile
Capital Stock70.4 K87 K50.4 K
Slightly volatile
Short Term Debt4.8 M9.2 M1.7 M
Slightly volatile
Current Deferred Revenue2.3 M2.6 M2.8 M
Slightly volatile

NRx Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.8 KK654.5 K
Slightly volatile
Other Operating Expenses32.9 M27.6 M14.7 M
Slightly volatile
Cost Of Revenue4.8 KK725.9 K
Slightly volatile
Total Operating Expenses32.9 M27.6 M14.7 M
Slightly volatile
Selling General Administrative28.2 M14.2 M10.4 M
Slightly volatile
Research Development13.5 M13.4 MM
Slightly volatile
Reconciled Depreciation3.6 KK2.4 K
Slightly volatile
Selling And Marketing ExpensesK4.5 K4.9 K
Slightly volatile

NRx Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow21.1 M20.1 MM
Slightly volatile
End Period Cash Flow8.6 M4.6 M4.4 M
Slightly volatile
Stock Based Compensation367.6 K387 K860.5 K
Slightly volatile
Depreciation2.9 KK1.1 K
Slightly volatile
Net Borrowings576.2 K648.2 K705.9 K
Slightly volatile
Total Cashflows From Investing Activities20.9 M23.6 M25.7 M
Slightly volatile
Cash And Cash Equivalents Changes368414451
Slightly volatile
Issuance Of Capital Stock8.9 M9.4 M7.1 M
Slightly volatile
Other Cashflows From Investing Activities21.2 M23.8 M25.9 M
Slightly volatile
Change To Netincome131.4 K147.8 K161 K
Slightly volatile
Change To Liabilities271.3 K305.2 K332.4 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables1.5 M1.7 M1.8 M
Slightly volatile
Capex To Depreciation0.570.63.468
Slightly volatile
Payables Turnover0.0010.00111.1345
Slightly volatile
Cash Per Share0.580.606550.6448
Slightly volatile
Days Payables Outstanding635.9 K605.6 K172.8 K
Slightly volatile
Current Ratio0.340.36143.4189
Slightly volatile
Graham Number12.2511.775812.6344
Slightly volatile
Capex Per Share4.0E-44.0E-41.0E-4
Slightly volatile
Interest Debt Per Share1.111.2250.8883
Very volatile
Debt To Assets1.311.25240.227
Slightly volatile
Days Of Payables Outstanding635.9 K605.6 K172.8 K
Slightly volatile
Effective Tax Rate3.0E-43.0E-40.2039
Pretty Stable
Quick Ratio0.340.36143.4187
Slightly volatile
Net Income Per E B T0.60.99970.7694
Pretty Stable
Cash Ratio0.230.24122.8427
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.00011.0068
Slightly volatile
Debt Ratio1.311.25240.227
Slightly volatile

NRx Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap33.1 M34.9 M1.8 B
Slightly volatile
Enterprise Value37.4 M39.4 M1.8 B
Slightly volatile

NRx Fundamental Market Drivers

Cash And Short Term Investments4.6 M

About NRx Pharmaceuticals Financial Statements

NRx Pharmaceuticals investors use historical fundamental indicators, such as NRx Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NRx Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.6 M2.3 M
Cost Of RevenueK4.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NRx Stock Analysis

When running NRx Pharmaceuticals' price analysis, check to measure NRx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRx Pharmaceuticals is operating at the current time. Most of NRx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRx Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.